FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Herndon

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Emil Lou; Katherine B Peters; David A Reardon; Ashley L Sumrall; Scott Turner; Leighann Bailey; April Coan; Annick Desjardins; Henry S Friedman; James E Herndon; Eric S Lipp; James J Vredenburgh
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
James E Herndon; Jimmie C Holland; Alice B Kornblith; Electra D Paskett
Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.
Luis A Sanchez-Perez; Robert J Schmittling; David Snyder; Gary E Archer; Darell D Bigner; Bryan D Choi; Xiuyu Cui; Catherine Flores; James E Herndon; Laura A Johnson; Duane A Mitchell; John H Sampson
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Herndon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Emil Lou; Katherine B Peters; David A Reardon; Ashley L Sumrall; Scott Turner; Leighann Bailey; April Coan; Annick Desjardins; Henry S Friedman; James E Herndon; Eric S Lipp; James J Vredenburgh
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Cancer medicine 2013;2(2):185-95.
2013: James E Herndon; Jimmie C Holland; Alice B Kornblith; Electra D Paskett
Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.
Psycho-oncology 2013;22(2):315-23.
2013: Luis A Sanchez-Perez; Robert J Schmittling; David Snyder; Gary E Archer; Darell D Bigner; Bryan D Choi; Xiuyu Cui; Catherine Flores; James E Herndon; Laura A Johnson; Duane A Mitchell; John H Sampson
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
PloS one 2013;8(3):e59082.
2013: April K S Salama; Randall P Scheri; Douglas S Tyler; Nicole de Rosa; James E Herndon; Jennifer Marcello; Scott K Pruitt; Amy P Abernethy
Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy.
PloS one 2013;8(3):e57665.
2013: Ali Zomorodi; James E Herndon; John H Sampson
Subarachnoid hemorrhage trials.
Journal of neurosurgery 2013;118(1):1-2; discussion 2.
2012: April K S Salama; Randall P Scheri; Douglas S Tyler; James E Herndon; Jennifer Marcello; Scott K Pruitt; Nicole de Rosa; Amy P Abernethy
The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost.
Cancer investigation 2012;30(9):637-41.
2012: David A Reardon; Jeremy Rich; John H Sampson; Sith Sathornsumetee; A L Sumrall; S Turner; Darell D Bigner; S T Boulton; A Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; E S Lipp; E Lou; K B Peters; James J Vredenburgh
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
British journal of cancer 2012;107(9):1481-7.
2012: David A Reardon; Jeremy N Rich; Sith Sathornsumetee; James J Vredenburgh; Sridharan Gururangan; James E Herndon; Dorothea Janney; Eric S Lipp; Roger McLendon; Katherine B Peters; April Coan; Annick Desjardins; Henry S Friedman
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Cancer 2012;118(19):4759-67.
2012: Win J Tcheung; Maria A Selim; Amy P Abernethy; James E Herndon; Kelly C Nelson
Clinicopathologic study of 85 cases of melanoma of the female genitalia.
Journal of the American Academy of Dermatology 2012;67(4):598-605.
2012: Michelle Pearce; April D Coan; James E Herndon; Harold G Koenig; Amy P Abernethy
Unmet spiritual care needs impact emotional and spiritual well-being in advanced cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2012;20(10):2269-76.
2012: Emil Lou; Roger E McLendon; Frances McSherry; Julie Norfleet; Katherine B Peters; Annick Desjardins; Henry S Friedman; James E Herndon; Ashley L Sumrall; Scott Turner; James J Vredenburgh; David A Reardon
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Journal of neuro-oncology 2012;109(1):63-70.
2012: David A Reardon; John H Sampson; Stevie Threatt; James J Vredenburgh; Anuradha Bulusu; Annick Desjardins; Allan H Friedman; Sridharan Gururangan; James E Herndon; Roger E McLendon; Katherine B Peters; Henry S Friedman
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Journal of neuro-oncology 2012;107(1):155-64.
2012: Annick Desjardins; Henry S Friedman; James E Herndon; Jennifer Marcello; Katherine B Peters; David A Reardon; Leighann Bailey; April Coan; James J Vredenburgh
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Cancer 2012;118(5):1302-12.
2012: John H Sampson; Robert J Schmittling; James J Vredenburgh; Smita K Nair; Elizabeth A Reap; David A Reardon; Gary E Archer; Darell D Bigner; April Coan; Kendra L Congdon; Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Duane A Mitchell
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
PloS one 2012;7(2):e31046.
2012: David A Reardon; John H Sampson; James J Vredenburgh; Patrick Y Wen; April Coan; Annick Desjardins; Jan Drappatz; Sridharan Gururangan; James E Herndon; Eric S Lipp; Roger E McLendon; Andrew D Norden; Julie A Norfleet; Katherine B Peters; Henry S Friedman
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Journal of neuro-oncology 2012;106(2):409-15.
2011: David A Reardon; Jeremy N Rich; Sith Sathornsumetee; James J Vredenburgh; April Coan; Annick Desjardins; Sridharan Gururangan; James E Herndon; Katherine B Peters; Henry S Friedman
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Journal of neuro-oncology 2011;105(3):621-7.
2011: Annick Desjardins; Allan H Friedman; Henry S Friedman; James E Herndon; Katherine B Peters; David A Reardon; Stevie Threatt; April D Coan; James J Vredenburgh
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Journal of neuro-oncology 2011;105(3):601-6.
2011: David A Reardon; John H Sampson; Stevie Threatt; James J Vredenburgh; April Coan; Annick Desjardins; Allan H Friedman; Sridharan Gururangan; James E Herndon; Roger E McLendon; Katherine B Peters; Henry S Friedman
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Cancer 2011;117(23):5351-8.
2011: Elizabeth B Gottlin; James E Herndon; Rex C Bentley; Michael J Campa; David S Pisetsky; Edward F Patz
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(10):1687-90.
2011: Emily Ruden; James J Vredenburgh; Emily Waner; Miranda West; Katherine B Peters; David A Reardon; April D Coan; Annick Desjardins; Diane R Fels; Allan H Friedman; Henry S Friedman; James E Herndon; Whitney E Hornsby; Lee W Jones
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(21):2918-23.
2011: Chien-Tsun Kuan; Kenji Wakiya; Stephen T Keir; Jianjun Li; James E Herndon; Ira Pastan; Darell D Bigner
Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
International journal of cancer. Journal international du cancer 2011;129(1):111-21.
2011: James J Vredenburgh; Leighann Bailey; Darell D Bigner; Annick Desjardins; Allan H Friedman; James E Herndon; John P Kirkpatrick; Jennifer Marcello; Katherine B Peters; David A Reardon; John H Sampson; Stevie Threatt; Henry S Friedman
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(12):4119-24.
2011: David A Reardon; Annick Desjardins; Katherine Peters; Sridharan Gururangan; John Sampson; Jeremy Rich; Roger McLendon; James E Herndon; Jennifer Marcello; Stevie Threatt; Allan H Friedman; James J Vredenburgh; Henry S Friedman
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Journal of neuro-oncology 2011;103(2):371-9.
2011: John H Sampson; James E Herndon
Resection of vestibular schwannomas.
Journal of neurosurgery 2011;114(5):1216-7; discussion 1217.
2011: David A Reardon; Scott Turner; Katherine B Peters; Annick Desjardins; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Lee W Jones; John P Kirkpatrick; Allan H Friedman; James J Vredenburgh; Darell D Bigner; Henry S Friedman
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(4):414-27.
2011: John H Sampson; Kenneth Aldape; Gary E Archer; April Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner; Amy B Heimberger
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro-oncology 2011;13(3):324-33.
2011: David A Reardon; James J Vredenburgh; Annick Desjardins; Katherine Peters; Sridharan Gururangan; John H Sampson; Jennifer Marcello; James E Herndon; Roger E McLendon; Dorothea Janney; Allan H Friedman; Darell D Bigner; Henry S Friedman
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Journal of neuro-oncology 2011;101(1):57-66.
2010: Sith Sathornsumetee; Annick Desjardins; James J Vredenburgh; Roger E McLendon; Jennifer Marcello; James E Herndon; Alyssa Mathe; Marta Hamilton; Jeremy Rich; Julie A Norfleet; Sridharan Gururangan; Henry S Friedman; David A Reardon
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Neuro-oncology 2010;12(12):1300-10.
2010: John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4722-9.
2010: Lee W Jones; Dorothy Watson; James E Herndon; Neil D Eves; Benjamin E Haithcock; Gregory Loewen; Leslie Kohman
Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer.
Cancer 2010;116(20):4825-32.
2010: Amy P Abernethy; Syed Yousuf Zafar; Hope Uronis; Jane L Wheeler; April Coan; Krista Rowe; Rebecca A Shelby; Robin Fowler; James E Herndon
Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients.
Journal of pain and symptom management 2010;40(4):545-58.
2010: Dale Ding; James E Herndon; Charles W Kanaly; Raghu Raghavan; Thomas J Cummings; John H Sampson
Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.
Neurological research 2010;32(8):810-5.
2010: Amy P Abernethy; Christine McDonald; Peter Frith; Katherine Clark; James E Herndon; Jennifer Marcello; Iven H Young; Janet Bull; Andrew Wilcock; Sara Booth; Jane L Wheeler; James A Tulsky; Alan J Crockett; david currow
Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial.
Lancet 2010;376(9743):784-93.
2010: John H Sampson; Gary Archer; Christoph Pedain; Eva Wembacher-Schröder; Manfred Westphal; Sandeep Kunwar; Michael A Vogelbaum; April Coan; James E Herndon; Raghu Raghavan; Martin L Brady; David A Reardon; Allan H Friedman; Henry S Friedman; M Inmaculada Rodríguez-Ponce; Susan M Chang; Stephan Mittermeyer; David Croteau; Raj K Puri
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Journal of neurosurgery 2010;113(2):301-9.
2010: Daphne R Friedman; April D Coan; Sophia K Smith; James E Herndon; Amy P Abernethy
Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians.
American journal of hematology 2010;85(7):528-32.
2010: Amy P Abernethy; James E Herndon; April Coan; Tina Staley; Jane L Wheeler; Krista Rowe; Sophia K Smith; H Shaw; H Kim Lyerly
Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2010;18(7):893-8.
2010: Dale Ding; Charles W Kanaly; Darrell D Bigner; Thomas J Cummings; James E Herndon; Ira Pastan; Raghu Raghavan; John H Sampson
Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.
Journal of neuro-oncology 2010;98(1):1-7.
2010: Lee W Jones; Benjamin L Viglianti; Jessica A Tashjian; Sejal M Kothadia; Stephen T Keir; Stephen J Freedland; Michael Q Potter; Eui Jung Moon; Thies Schroeder; James E Herndon; Mark W Dewhirst
Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer.
Journal of applied physiology (Bethesda, Md. : 1985) 2010;108(2):343-8.
2010: Lee W Jones; Pamela S Douglas; Neil D Eves; P Kelly Marcom; William E Kraus; James E Herndon; Brant A Inman; Jason D Allen; Jeffrey Peppercorn
Rationale and design of the Exercise Intensity Trial (EXCITE): A randomized trial comparing the effects of moderate versus moderate to high-intensity aerobic training in women with operable breast cancer.
BMC cancer 2010;10():531.
2010: Chien-Tsun Kuan; Kenji Wakiya; James E Herndon; Eric S Lipp; Charles N Pegram; Gregory J Riggins; Ahmed Rasheed; Scott E Szafranski; Roger E McLendon; Carol J Wikstrand; Darell D Bigner
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
BMC cancer 2010;10():468.
2010: Syed Yousuf Zafar; Jennifer E Marcello; Jane L Wheeler; Krista L Rowe; Michael A Morse; James E Herndon; Amy P Abernethy
Treatment-related toxicity and supportive care in metastatic colorectal cancer.
The journal of supportive oncology 2010;8(1):15-20.
2010: David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; Allan H Friedman; James E Herndon; Jennifer Marcello; Julie A Norfleet; Roger E McLendon; John H Sampson; Henry S Friedman
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Journal of neuro-oncology 2010;96(2):219-30.
2009: David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Sith Sathornsumetee; Roger E McLendon; James E Herndon; J E Marcello; J Norfleet; Allan H Friedman; Darell D Bigner; Henry S Friedman
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
British journal of cancer 2009;101(12):1986-94.
2009: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Journal of neuro-oncology 2009;95(3):393-400.
2009: John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; James E Herndon; Denise Lally-Goss; Sharon McGehee-Norman; Alison Paolino; David A Reardon; Allan H Friedman; Henry S Friedman; Darell D Bigner
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Molecular cancer therapeutics 2009;8(10):2773-9.
2009: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Amy Walker; Henry S Friedman
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Neuro-oncology 2009;11(5):556-61.
2009: Syed Yousuf Zafar; Jennifer E Marcello; Jane L Wheeler; Krista L Rowe; Michael A Morse; James E Herndon; Amy P Abernethy
Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.
Journal of oncology practice / American Society of Clinical Oncology 2009;5(5):228-33.
2009: Mary Lou Affronti; Christopher R Heery; James E Herndon; Jeremy Rich; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; Darell D Bigner; Henry S Friedman
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Cancer 2009;115(15):3501-11.
2009: Amy P Abernethy; James E Herndon; Jane L Wheeler; Krista Rowe; Jennifer Marcello; Meenal B Patwardhan
Poor documentation prevents adequate assessment of quality metrics in colorectal cancer.
Journal of oncology practice / American Society of Clinical Oncology 2009;5(4):167-74.
2009: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Cancer 2009;115(13):2964-70.
2009: David A Reardon; Merrill J Egorin; Annick Desjardins; James J Vredenburgh; Jan H Beumer; Theodore F Lagattuta; Sridharan Gururangan; James E Herndon; August J Salvado; Henry S Friedman
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Cancer 2009;115(10):2188-98.
2009: Alexandra Dupont; Jane Wheeler; James E Herndon; April Coan; Syed Yousuf Zafar; Linda Hood; Meenal B Patwardhan; Heather S Shaw; H Kim Lyerly; Amy P Abernethy
Use of tablet personal computers for sensitive patient-reported information.
The journal of supportive oncology 2009;7(3):91-7.
2008: Robert J Schmittling; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Charles N Pegram; James E Herndon; Henry S Friedman; Darell D Bigner; John H Sampson
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Journal of immunological methods 2008;339(1):74-81.
2008: Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7068-73.
2008: Jeffrey A. Bogart; Dorothy Watson; Edward F McClay; Lisa Evans; James E Herndon; Frances Laurie; Stephen L Seagren; T J Fitzgerald; Everett Vokes; Mark R Green
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.
Lung cancer (Amsterdam, Netherlands) 2008;62(1):92-8.
2008: James E Herndon; Alice B Kornblith; Jimmie C Holland; Electra D Paskett
Patient education level as a predictor of survival in lung cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4116-23.
2008: John H Sampson; Gamal Akabani; Gary E Archer; Mitchel S Berger; R Edward Coleman; Allan H Friedman; Henry S Friedman; Kim Greer; James E Herndon; Sandeep Kunwar; Roger E McLendon; Alison Paolino; Neil Petry; James M Provenzale; David A Reardon; Terence Z Wong; Michael R Zalutsky; Ira Pastan; Darell D Bigner
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Neuro-oncology 2008;10(3):320-9.
2008: David A Reardon; Annick Desjardins; James J Vredenburgh; Sith Sathornsumetee; Jeremy Rich; Jennifer A Quinn; Theodore F Lagattuta; Merrill J Egorin; Sridharan Gururangan; Roger E McLendon; James E Herndon; Allan H Friedman; August J Salvado; Henry S Friedman
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Neuro-oncology 2008;10(3):330-40.
2008: Staci D Arnold; Leslie M Forman; Bart D Brigidi; Karen E Carter; Holly A Schweitzer; Heather E Quinn; A Bebe Guill; James E Herndon; Renee H Raynor
Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors.
Neuro-oncology 2008;10(2):171-81.
2008: David A Reardon; Michael R Zalutsky; Gamal Akabani; R Edward Coleman; Allan H Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; Jennifer A Quinn; Jeremy Rich; James J Vredenburgh; Annick Desjardins; Sridharan Guruangan; Susan Boulton; Renee H Raynor; Jeannette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Henry S Friedman; Darell D Bigner
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Neuro-oncology 2008;10(2):182-9.
2008: Jenny Hoang; Luke F Hoagland; R Edward Coleman; April D Coan; James E Herndon; Edward F Patz
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(9):1459-64.
2008: Elizabeth B Lamont; James E Herndon; Jane C Weeks; I Craig Henderson; Rogerio Lilenbaum; Richard L Schilsky; Nicholas A Christakis
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
Medical care 2008;46(3):303-8.
2008: Stephen L Graziano; James E Herndon; Mark A Socinski; Xiaofei Wang; Dorothy Watson; Everett Vokes; Mark R Green
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):158-62.
2008: Sith Sathornsumetee; Yiting Cao; Jennifer E Marcello; James E Herndon; Roger E McLendon; Annick Desjardins; Henry S Friedman; Mark Dewhirst; James J Vredenburgh; Jeremy Rich
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):271-8.
2008: Syed Yousuf Zafar; Amy P Abernethy; David H Abbott; Steven C Grambow; Jennifer E Marcello; James E Herndon; Krista L Rowe; Jane T Kolimaga; Leah L Zullig; Meenal B Patwardhan; Dawn Provenzale
Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.
BMC cancer 2008;8():345.
2008: Hidenobu Ochiai; Gary E Archer; James E Herndon; Chien-Tsun Kuan; Duane A Mitchell; Darell D Bigner; Ira Pastan; John H Sampson
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
Cancer immunology, immunotherapy : CII 2008;57(1):115-21.
2007: Edward F Patz; Michael J Campa; Elizabeth B Gottlin; Irina Kusmartseva; Xiang Rong Guan; James E Herndon
Panel of serum biomarkers for the diagnosis of lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5578-83.
2007: Luke F M Hoagland; Michael J Campa; Elizabeth B Gottlin; James E Herndon; Edward F Patz
Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.
Cancer 2007;110(10):2260-8.
2007: James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4722-9.
2007: Corinne M Linardic; Sarasija Naini; James E Herndon; Chimen Kesserwan; Stephen J Qualman; Christopher M Counter
The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
Cancer research 2007;67(14):6691-9.
2007: John H Sampson; Raghu Raghavan; Martin L Brady; James M Provenzale; James E Herndon; David Croteau; Allan H Friedman; David A Reardon; R Edward Coleman; Terence Wong; Darell D Bigner; Ira Pastan; María Inmaculada Rodríguez-Ponce; Philipp Tanner; Raj Puri; Christoph Pedain
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
Neuro-oncology 2007;9(3):343-53.
2007: Richard F Riedel; Carolyn Andrews; Jennifer Garst; Frank Dunphy; James E Herndon; Susan Blackwell; Sally Barbour; Jeffrey Crawford
A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(6):520-5.
2007: Joerg Gauger; Edward F Patz; R Edward Coleman; James E Herndon
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(6):499-505.
2007: Roger E McLendon; Gamal Akabani; Henry S Friedman; David A Reardon; Linda Cleveland; Ilkcan Cokgor; James E Herndon; Carol J Wikstrand; Susan T Boulton; Allan H Friedman; Darell D Bigner; Michael R Zalutsky
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
Nuclear medicine and biology 2007;34(4):405-13.
2007: Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Sith Sathornsumetee; Allan H Friedman; James E Herndon; Roger E McLendon; James M Provenzale; Jeremy Rich; John H Sampson; Sridharan Gururangan; Jeannette M Dowell; August Salvado; Henry S Friedman; David A Reardon
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Journal of neuro-oncology 2007;83(1):53-60.
2007: Sridharan Gururangan; Michael J Fisher; Jeffrey C Allen; James E Herndon; Jennifer A Quinn; David A Reardon; James J Vredenburgh; Annick Desjardins; Peter C Phillips; Melody Watral; Jeanne M Krauser; Allan H Friedman; Henry S Friedman
Temozolomide in children with progressive low-grade glioma.
Neuro-oncology 2007;9(2):161-8.
2007: James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1253-9.
2007: Michael A Badruddoja; Kara Penne; Annick Desjardins; David A Reardon; Jeremy Rich; Jennifer A Quinn; Sith Sathornsumetee; Allan H Friedman; Darell D Bigner; James E Herndon; Ann Cahill; Henry S Friedman; James J Vredenburgh
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
Neuro-oncology 2007;9(1):70-4.
2006: Richard F Riedel; Jeffrey Crawford; Frank Dunphy; James E Herndon; Jennifer Garst; Michael J Kelley
Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2006;54(3):431-2.
2006: Gordana Vlahovic; Zahid Rabbani; James E Herndon; Mark Dewhirst; Zeljko Vujaskovic
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
British journal of cancer 2006;95(8):1013-9.
2006: Jill A Maxwell; Stewart P Johnson; Jennifer A Quinn; Roger E McLendon; Francis Ali-Osman; Allan H Friedman; James E Herndon; Katja Bierau; Joseph Bigley; Darell D Bigner; Henry S Friedman
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.
Molecular cancer therapeutics 2006;5(10):2531-9.
2006: Mitchell S. Anscher; Jennifer Garst; Lawrence Marks; Nicole Larrier; Frank Dunphy; James E Herndon; Robert Clough; Christine Marino; Zeljko Vujaskovic; Sumin Zhou; Mark Dewhirst; Timothy D Shafman; Jeffrey Crawford
Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.
International journal of radiation oncology, biology, physics 2006;66(2):477-82.
2006: Wendy R Cornett; Linda M McCall; Rebecca P Petersen; Merrick I Ross; Henry A. Briele; R Dirk Noyes; Jeffrey J Sussman; William G Kraybill; John M Kane; H Richard Alexander; Jeffrey E Lee; Paul F Mansfield; James F Pingpank; David J Winchester; Richard L White; Vijaya Chadaram; James E Herndon; Douglas L Fraker; Douglas S Tyler
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4196-201.
2006: David A Reardon; Jennifer A Quinn; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; James M Provenzale; Jeannette M Dowell; Jeremy Rich; James J Vredenburgh; Annick Desjardins; John H Sampson; Sridharan Gururangan; Terence Z Wong; Michael A Badruddoja; Xiao-Guang Zhao; Darell D Bigner; Michael R Zalutsky
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(6):912-8.
2006: Chien-Tsun Kuan; Kenji Wakiya; Jeannette M Dowell; James E Herndon; David A Reardon; Michael W Graner; Gregory J Riggins; Carol J Wikstrand; Darell D Bigner
Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1970-82.
2006: Lee G Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl Gabram-Mendola; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.
Annals of surgical oncology 2006;13(4):491-500.
2006: Peter E Fecci; Duane A Mitchell; John F Whitesides; Weihua Xie; Allan H Friedman; Gary E Archer; James E Herndon; Darell D Bigner; Glenn Dranoff; John H Sampson
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Cancer research 2006;66(6):3294-302.
2006: David A Reardon; Jennifer A Quinn; James J Vredenburgh; Sridharan Gururangan; Allan H Friedman; Annick Desjardins; Sith Sathornsumetee; James E Herndon; Jeannette M Dowell; Roger E McLendon; James M Provenzale; John H Sampson; Robert P Smith; Alan J Swaisland; Judith S Ochs; Peggy Lyons; Sandy Tourt-Uhlig; Darell D Bigner; Henry S Friedman; Jeremy Rich
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):860-8.
2006: A. William Blackstock; James E Herndon; Electra D Paskett; Antonius A Miller; Christopher S Lathan; Harvey B Niell; Mark A Socinski; Everett E Vokes; Mark R Green
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):407-12.
2006: Jennifer Garst; James E Herndon; Timothy D Shafman; Lara Campagna; Susan Blackwell; Karen Padilla; Toni Bjurstrom; Carolyn Andrews; Diana Maravich-May; Elizabeth Anderson; Jeffrey Crawford
A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
Clinical drug investigation 2006;26(5):257-66.
2006: David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Roger E McLendon; Charles N Pegram; James M Provenzale; Jennifer A Quinn; Jeremy Rich; James J Vredenburgh; Annick Desjardins; Sridharan Gururangan; Sri Guruangan; Michael A Badruddoja; Jeannette M Dowell; Terence Z Wong; Xiao-Guang Zhao; Michael R Zalutsky; Darell D Bigner
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):115-22.
2005: David A Reardon; Merrill J Egorin; Jennifer A Quinn; Jeremy Rich; Jeremy N Rich; Sridharan Gururangan; Idharan Gururangan; James J Vredenburgh; Annick Desjardins; Sith Sathornsumetee; James M Provenzale; James E Herndon; Jeannette M Dowell; Michael A Badruddoja; Roger E McLendon; Theodore F Lagattuta; Kimberly P Kicielinski; Gregor Dresemann; John H Sampson; Allan H Friedman; August J Salvado; Henry S Friedman
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9359-68.
2005: Roger E McLendon; James E Herndon; Bryan West; David Reardon; Rodney N Wiltshire; B K Ahmed Rasheed; Jennifer Quinn; Henry S Friedman; Allan H Friedman; Darell D Bigner
Survival analysis of presumptive prognostic markers among oligodendrogliomas.
Cancer 2005;104(8):1693-9.
2005: Katherine E Posther; Linda M McCall; Peter W Blumencranz; William E Burak; Peter D Beitsch; Nora M Hansen; Monica Morrow; Lee G Wilke; James E Herndon; Kelly K Hunt; Armando E Giuliano
Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.
Annals of surgery 2005;242(4):593-9; discussion 599-602.
2005: Jennifer A Quinn; Annick Desjardins; Jon D Weingart; Henry Brem; M Eileen Dolan; Shannon M Delaney; James J Vredenburgh; Jeremy Rich; Allan H Friedman; David A Reardon; John H Sampson; Anthony E Pegg; Robert C Moschel; Robert Birch; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Janet E Dancey; Jill Maxwell; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7178-87.
2005: A Marilyn Leitch; Peter D Beitsch; Linda M McCall; Katherine Posther; Lisa A Newman; James E Herndon; Kelly K Hunt; Armando E Giuliano
Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.
American journal of surgery 2005;190(4):539-42.
2005: David A Reardon; Jennifer A Quinn; Jeremy Rich; Annick Desjardins; James J Vredenburgh; Sridharan Gururangan; Sith Sathornsumetee; Michael A Badruddoja; Roger E McLendon; James M Provenzale; James E Herndon; Jeannette M Dowell; Jill L Burkart; Herbert B Newton; Allan H Friedman; Henry S Friedman
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Cancer 2005;104(7):1478-86.
2005: Wallace Akerley; James E Herndon; Alan P Lyss; Hak Choy; Andrew T Turrisi; Stephen Graziano; Todd Williams; Chunfeng Zhang; Everett E Vokes; Mark R Green
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
Clinical lung cancer 2005;7(1):47-53.
2005: Harvey B Niell; James E Herndon; Antonius A Miller; Dorothy M Watson; Alan B Sandler; Karen Kelly; Randolph S Marks; Michael C Perry; Rafat H Ansari; Gregory A Otterson; John Ellerton; Everett E Vokes; Mark R Green
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3752-9.
2005: Antonius A Miller; James E Herndon; Lin Gu; Mark R Green
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
Lung cancer (Amsterdam, Netherlands) 2005;48(3):399-407.
2005: Michael J Kelley; Elizabeth M Glaser; James E Herndon; Frank Becker; Rajesh Bhagat; Yu-Jing Zhang; Regina M Santella; Steven G Carmella; Stephen S Hecht; Lilia Gallot; Lawrence Schilder; James A Crowell; Marjorie Perloff; Rodney J Folz; Raymond C Bergan
Safety and efficacy of weekly oral oltipraz in chronic smokers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(4):892-9.
2005: Mary-Beth Moore Joshi; Yoshinori Shirota; Kathleen D Danenberg; Debbi H Conlon; Dennis Salonga; James E Herndon; Peter V Danenberg; David H Harpole
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2215-21.
2005: David A Reardon; Jennifer A Quinn; James J Vredenburgh; Jeremy Rich; Sridharan Gururangan; Michael A Badruddoja; James E Herndon; Jeannette M Dowell; Allan H Friedman; Henry S Friedman
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Cancer 2005;103(2):329-38.
2005: Rogerio Lilenbaum; James E Herndon; Marcy A List; Chris Desch; Dorothy M Watson; Antonius A Miller; Stephen L Graziano; Michael C Perry; Wayne Saville; Philippe Chahinian; Jane C Weeks; Jimmie C Holland; Mark R Green
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):190-6.
2004: Sridharan Gururangan; Eugene Hwang; James E Herndon; Herbert Fuchs; Timothy George; R Edward Coleman
[18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma.
Neurosurgery 2004;55(6):1280-8; discussion 1288-9.
2004: Brandon A Howard; Zhong Zheng; Michael J Campa; Zhuo Wang; Anupama Sharma; Eric Haura; James E Herndon; Michael C Fitzgerald; Gerold Bepler; Edward F Patz
Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;46(3):313-23.
2004: Lawrence Marks; Jennifer Garst; Mark A Socinski; Gregory S Sibley; A. William Blackstock; James E Herndon; Sunmin Zhou; Timothy D Shafman; Andrea Tisch; Robert Clough; Xiaoli Yu; Andrew Turrisi; Mitchell S. Anscher; Jeffrey Crawford; Julian G Rosenman
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4329-40.
2004: Rodney N Wiltshire; James E Herndon; Annie Lloyd; Henry S Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.
The Journal of molecular diagnostics : JMD 2004;6(3):166-79.
2004: Edward F Patz; Stephen J Swensen; James E Herndon
Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2202-6.
2004: Jeffrey A. Bogart; James E Herndon; Alan P Lyss; Dorothy Watson; Antonius A Miller; Michael E Lee; Andrew T Turrisi; Mark R Green
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.
International journal of radiation oncology, biology, physics 2004;59(2):460-8.
2004: Sendhil Kumar Cheran; James E Herndon; Edward F Patz
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;44(3):317-25.
2004: Jennifer A Quinn; David A Reardon; Allan H Friedman; Jeremy Rich; John H Sampson; James J Vredenburgh; Sridharan Gururangan; James M Provenzale; Amy Walker; Holly Schweitzer; Darell D Bigner; Sandra Tourt-Uhlig; James E Herndon; Mary Lou Affronti; Susanne Jackson; Deborah Allen; Karen Ziegler; Cindy Bohlin; Christy Lentz; Henry S Friedman
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Neuro-oncology 2004;6(2):145-53.
2004: David A Reardon; Jennifer A Quinn; Jeremy Rich; Sridharan Gururangan; James J Vredenburgh; John H Sampson; James M Provenzale; Amy Walker; Michael A Badruddoja; Sandra Tourt-Uhlig; James E Herndon; Jeannette M Dowell; Mary Lou Affronti; Susanne Jackson; Deborah Allen; Karen Ziegler; Steven Silverman; Cindy Bohlin; Allan H Friedman; Darell D Bigner; Henry S Friedman
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Neuro-oncology 2004;6(2):134-44.
2004: Edith M Marom; James E Herndon; Yun-Hyeon Kim; H Page McAdams
Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation.
Radiology 2004;230(3):824-9.
2004: Jeremy Rich; David A Reardon; Terry Peery; Jeannette M Dowell; Jennifer A Quinn; Kara Penne; Carol J Wikstrand; Lauren B Van Duyn; Janet E Dancey; Roger E McLendon; James C Kao; Timothy T Stenzel; B K Ahmed Rasheed; Sandra Tourt-Uhlig; James E Herndon; James J Vredenburgh; John H Sampson; Allan H Friedman; Darell D Bigner; Henry S Friedman
Phase II trial of gefitinib in recurrent glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):133-42.
2003: Susan H Bernacki; Ana K Stankovic; Laurina O Williams; Jeanne C Beck; James E Herndon; Karen Snow-Bailey; Thomas W Prior; Karla J Matteson; Linda M Wasserman; Eugene C Cole; Timothy T Stenzel
Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.
The Journal of molecular diagnostics : JMD 2003;5(4):227-30.
2003: John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James M Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy T Stenzel; Sandra Tourt-Uhlig; Carol J Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Journal of neuro-oncology 2003;65(1):27-35.
2003: Mitchell S. Anscher; Lawrence Marks; Timothy D Shafman; Robert Clough; Hong Huang; Andrea Tisch; Michael T Munley; James E Herndon; Jennifer Garst; Jeffrey Crawford; Randy L Jirtle
Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.
International journal of radiation oncology, biology, physics 2003;56(4):988-95.
2003: Kelli R Brooks; Kathleen To; Mary-Beth Moore Joshi; Debbi H Conlon; James E Herndon; Thomas A D'Amico; David H Harpole
Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.
The Annals of thoracic surgery 2003;76(1):187-93; discussion 193.
2003: Edith M Marom; Scott M Palmer; Jeremy J Erasmus; James E Herndon; Chunfeng Zhang; H Page McAdams
Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage.
Radiology 2003;228(1):241-5.
2003: Jennifer A Quinn; David A Reardon; Allan H Friedman; Jeremy Rich; John H Sampson; James M Provenzale; Roger E McLendon; Sridharan Gururangan; Darell D Bigner; James E Herndon; Nicholas Avgeropoulos; Jonathan Lester Finlay; Sandra Tourt-Uhlig; Mary Lou Affronti; Brandon Evans; Valerie Stafford-Fox; Sara Zaknoen; Henry S Friedman
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2002: Sridharan Gururangan; Christina M Cavazos; David Ashley; James E Herndon; Carol S Bruggers; Albert Moghrabi; Deborah L Scarcella; Melody Watral; Sandra Tourt-Uhlig; David Reardon; Henry S Friedman
Phase II study of carboplatin in children with progressive low-grade gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2951-8.
2002: Edith M Marom; Jeremy J Erasmus; James E Herndon; Chunfeng Zhang; H Page McAdams
Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.
AJR. American journal of roentgenology 2002;179(1):105-8.
2002: Ahmed Rasheed; James E Herndon; Timothy T Stenzel; Jacqueline G M Raetz; Jason Kendelhardt; Henry S Friedman; Allan H Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Molecular markers of prognosis in astrocytic tumors.
Cancer 2002;94(10):2688-97.
2002: Edith M Marom; Sarah Sarvis; James E Herndon; Edward F Patz
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.
Radiology 2002;223(2):453-9.
2002: Jennifer A Quinn; James Pluda; M Eileen Dolan; Shannon M Delaney; Richard S. Kaplan; Jeremy Rich; Allan H Friedman; David A Reardon; John H Sampson; O Michael Colvin; Michael M Haglund; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; Sridharan Gururangan; Sandra Tourt-Uhlig; James E Herndon; Darell D Bigner; Henry S Friedman
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2277-83.
2002: David A Reardon; Gamal Akabani; R Edward Coleman; Allan H Friedman; Henry S Friedman; James E Herndon; Ilkcan Cokgor; Roger E McLendon; Charles N Pegram; James M Provenzale; Jennifer A Quinn; Jeremy Rich; Lorna V Regalado; John H Sampson; Timothy D Shafman; Carol J Wikstrand; Terence Z Wong; Xiao-Guang Zhao; Michael R Zalutsky; Darell D Bigner
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1389-97.
2002: A. William Blackstock; James E Herndon; Electra D Paskett; Michael C Perry; Stephen L Graziano; Joseph J Muscato; Michael P Kosty; Wallace Akerley; Jimmie C Holland; Stewart Fleishman; Mark R Green
Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.
Journal of the National Cancer Institute 2002;94(4):284-90.
2002: Alan P Lyss; James E Herndon; Thomas J Lynch; Andrew T Turrisi; Dorothy M Watson; Sara J Grethlein; Mark R Green
Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).
Clinical lung cancer 2002;3(3):205-10; discussion 211-2.
2001: Laura E Heyneman; James E Herndon; Philip C Goodman; Edward F Patz
Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening.
Cancer 2001;92(12):3051-5.
2001: Thomas A D'Amico; Thomas A Aloia; Mary-Beth H Moore; Debbi H Conlon; James E Herndon; Michael S Kinch; David H Harpole
Predicting the sites of metastases from lung cancer using molecular biologic markers.
The Annals of thoracic surgery 2001;72(4):1144-8.
2001: Sridharan Gururangan; L Cokgor; Jeremy Rich; S Edwards; Mary Lou Affronti; Jennifer A Quinn; James E Herndon; James M Provenzale; Roger E McLendon; Sandra Tourt-Uhlig; John H Sampson; V Stafford-Fox; Sara Zaknoen; M Early; Allan H Friedman; Henry S Friedman
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Neuro-oncology 2001;3(4):246-50.
2001: Thomas A Aloia; David H Harpole; Carolyn E Reed; C Allegra; Mary-Beth H Moore; James E Herndon; Thomas A D'Amico
Tumor marker expression is predictive of survival in patients with esophageal cancer.
The Annals of thoracic surgery 2001;72(3):859-66.
2001: Mitchell S. Anscher; Lawrence Marks; Timothy D Shafman; Robert Clough; Hong Huang; Andrea Tisch; Michael T Munley; James E Herndon; Jennifer Garst; Jeffrey Crawford; Randy L Jirtle
Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3758-65.
2001: Stephen L Graziano; Arthur H Tatum; James E Herndon; J Box; V Memoli; Mark R Green; J A Kern
Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.
Lung cancer (Amsterdam, Netherlands) 2001;33(2-3):115-23.
2001: Edith M Marom; Thomas A Aloia; Mary-Beth H Moore; M Hara; James E Herndon; David H Harpole; Philip C Goodman; Edward F Patz
Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;33(2-3):99-107.
2001: David H Harpole; Mary-Beth H Moore; James E Herndon; Thomas A Aloia; Thomas A D'Amico; Thomas A Sporn; A Parr; I Linoila; C Allegra
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):562-9.
2001: PD Maguire; Lawrence Marks; Gregory S Sibley; James E Herndon; Robert W Clough; Kim L Light; Maria Lourdes Hernando; P A Antoine; Mitchell S. Anscher
73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):705-11.
2001: Thomas A Aloia; Gerold Bepler; David H Harpole; Philip C Goodman; H P McAdams; J J Erasmus; James E Herndon; Edward F Patz
Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities.
Cancer detection and prevention 2001;25(4):336-43.
2000: Ilkcan Cokgor; Gamal Akabani; Chien-Tsun Kuan; Henry S Friedman; Allan H Friedman; R Edward Coleman; Roger E McLendon; Sandra H Bigner; Xiao-Guang Zhao; AM Garcia-Turner; Charles N Pegram; Carol J Wikstrand; Timothy D Shafman; James E Herndon; James M Provenzale; Michael R Zalutsky; Darell D Bigner
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(22):3862-72.
2000: Henry S Friedman; James Pluda; Jennifer A Quinn; Reginald Ewesuedo; L Long; Allan H Friedman; Ilkcan Cokgor; O Michael Colvin; Michael M Haglund; DM Ashley; Jeremy Rich; J Sampson; Anthony E Pegg; Robert C Moschel; Roger E McLendon; James M Provenzale; ES Stewart; Sandra Tourt-Uhlig; AM Garcia-Turner; James E Herndon; Darell D Bigner; M Eileen Dolan
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3522-8.
2000: M A Farrell; H Page McAdams; James E Herndon; Edward F Patz
Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
Radiology 2000;215(3):886-90.
2000: Thomas A D'Amico; Thomas A Aloia; Mary-Beth H Moore; James E Herndon; Kelli R Brooks; Christine L Lau; David H Harpole
Molecular biologic substaging of stage I lung cancer according to gender and histology.
The Annals of thoracic surgery 2000;69(3):882-6.
2000: Gamal Akabani; Ilkcan Cokgor; R Edward Coleman; D González Trotter; Terence Z Wong; Henry S Friedman; Allan H Friedman; AM Garcia-Turner; James E Herndon; David DeLong; Roger E McLendon; Xiao-Guang Zhao; Charles N Pegram; James M Provenzale; Darell D Bigner; Michael R Zalutsky
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
International journal of radiation oncology, biology, physics 2000;46(4):947-58.
1999: Edith M Marom; H Page McAdams; Jeremy J Erasmus; Philip C Goodman; DK Culhane; R Edward Coleman; James E Herndon; Edward F Patz
Staging non-small cell lung cancer with whole-body PET.
Radiology 1999;212(3):803-9.
1999: PD Maguire; Gregory S Sibley; Su-Min Zhou; Timothy A Jamieson; Kim L Light; P A Antoine; James E Herndon; Mitchell S. Anscher; Lawrence Marks
Clinical and dosimetric predictors of radiation-induced esophageal toxicity.
International journal of radiation oncology, biology, physics 1999;45(1):97-103.
1999: Edward F Patz; Jeremy J Erasmus; H Page McAdams; JE Connolly; Edith M Marom; Philip C Goodman; Richard A Leder; Mary T Keogan; James E Herndon
Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax.
Radiology 1999;212(1):56-60.
1999: Thomas A D'Amico; Marga F Massey; James E Herndon; Mary-Beth H Moore; David H Harpole
A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.
The Journal of thoracic and cardiovascular surgery 1999;117(4):736-43.
1999: James E Herndon; Stewart Fleishman; Alice B Kornblith; Michael P Kosty; Mark R Green; Jimmie C Holland
Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?
Cancer 1999;85(2):333-40.
1999: Edith M Marom; Edward F Patz; Jeremy J Erasmus; H Page McAdams; Philip C Goodman; James E Herndon
Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis.
Radiology 1999;210(1):277-81.
1998: Henry S Friedman; Demetrius M Kokkinakis; James Pluda; Allan H Friedman; Ilkcan Cokgor; Michael M Haglund; DM Ashley; Jeremy Rich; M Eileen Dolan; Anthony E Pegg; Robert C Moschel; Roger E McLendon; T Kerby; James E Herndon; Darell D Bigner; S Clifford Schold
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3570-5.
1998: Noah C Choi; James E Herndon; Julian G Rosenman; RW Carey; C T Chung; S Bernard; L Leone; S Seagren; M Green
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(11):3528-36.
1998: James E Herndon
A design alternative for two-stage, phase II, multicenter cancer clinical trials.
Controlled clinical trials 1998;19(5):440-50.
1998: Stephen L Graziano; J A Kern; James E Herndon; Arthur H Tatum; M L Brisson; V Memoli; D Sugarbaker; Arthur T Skarin; H Kreisman; Mark R Green
Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.
Lung cancer (Amsterdam, Netherlands) 1998;21(3):203-11.
1998: SA Mehdi; M C Perry; James E Herndon; Jeffrey Crawford; R Young; Stephen L Graziano
A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1998;18(8):623-7.
1998: Michael C Perry; James E Herndon; WL Eaton; Mark R Green
Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2466-7.
1998: Darell D Bigner; M T Brown; Allan H Friedman; R Edward Coleman; Gamal Akabani; Henry S Friedman; W L Thorstad; Roger E McLendon; Sandra H Bigner; Xiao-Guang Zhao; Charles N Pegram; Carol J Wikstrand; James E Herndon; N A Vick; Nina Paleologos; Ilkcan Cokgor; James M Provenzale; Michael R Zalutsky
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(6):2202-12.
1998: Mark Graham II; Barbara L Asselin; James E Herndon; J R Casey; S Chaffee; Gilbert Ciocci; Charles Daeschner; A R Davis; Stuart Gold; Edward C Halperin; Mary J Laughlin; Paul L Martin; J F Olson; Joanne Kurtzberg
Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.
Bone marrow transplantation 1998;21(9):879-85.
1997: LH Maurer; James E Herndon; D R Hollis; Joseph Aisner; RW Carey; Arthur T Skarin; Michael C Perry; WL Eaton; L L Zacharski; S Hammond; Mark R Green
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(11):3378-87.
1997: James E Herndon; Stewart Fleishman; Michael P Kosty; Mark R Green
A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.
Controlled clinical trials 1997;18(4):286-300.
1997: M L Graham; James E Herndon; J R Casey; S Chaffee; Gilbert Ciocci; J P Krischer; Joanne Kurtzberg; Mary J Laughlin; DC Longee; J F Olson; N Paleologus; C N Pennington; Henry S Friedman
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1814-23.